Last edition
News about "Armlupeg "
Lupin and Valorum Enter into Licensing Agreement for Armlupeg in US
Under the terms of the agreement, Valorum will advance the commercialisation and distribution of Armlupeg (pegfilgrastim-unne) in the US. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront licence fee and a royalty payment on net sales.
Armlupeg | 05/12/2025 | By Dineshwori
Lupin Secures US FDA Approval for Pegfilgrastim Biosimilar Armlupeg
Lupin has received approval from the U.S. Food and Drug Administration (FDA) for its biosimilar Armlupeg (pegfilgrastim-unne), marking an important milestone in the company’s biologics journey. Armlupeg is a biosimilar to Neulasta (pegfilgrastim), a widely used therapy that helps reduce infection risk in cancer patients undergoing chemotherapy.
Armlupeg | 01/12/2025 | By Darshana | 162
Lupin Secures Health Canada Approval for Biosimilar Pegfilgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim.
Armlupeg | 26/08/2024 | By Aishwarya | 407
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy